# A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

> **NCT04609826** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 153 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** JNJ-74856665
- **DRUG:** AZA
- **DRUG:** VEN

## Key facts

- **NCT ID:** NCT04609826
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-26
- **Primary completion:** 2025-08-25
- **Final completion:** 2025-08-25
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04609826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04609826, "A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04609826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*